| Literature DB >> 27052162 |
Yuliya V Katlinskaya1, Kanstantsin V Katlinski1, Qiujing Yu1, Angelica Ortiz1, Daniel P Beiting2, Angela Brice2, Diwakar Davar3, Cindy Sanders3, John M Kirkwood3, Hallgeir Rui4, Xiaowei Xu5, Constantinos Koumenis6, J Alan Diehl7, Serge Y Fuchs8.
Abstract
Oncogene activation induces DNA damage responses and cell senescence. We report a key role of type I interferons (IFNs) in oncogene-induced senescence. IFN signaling-deficient melanocytes expressing activated Braf do not exhibit senescence and develop aggressive melanomas. Restoration of IFN signaling in IFN-deficient melanoma cells induces senescence and suppresses melanoma progression. Additional data from human melanoma patients and mouse transplanted tumor models suggest the importance of non-cell-autonomous IFN signaling. Inactivation of the IFN pathway is mediated by the IFN receptor IFNAR1 downregulation that invariably occurs during melanoma development. Mice harboring an IFNAR1 mutant, which is partially resistant to downregulation, delay melanoma development, suppress metastatic disease, and better respond to BRAF or PD-1 inhibitors. These results suggest that IFN signaling is an important tumor-suppressive pathway that inhibits melanoma development and progression and argue for targeting IFNAR1 downregulation to prevent metastatic disease and improve the efficacy of molecularly target and immune-targeted melanoma therapies.Entities:
Keywords: BRAF; interferon receptor; melanoma; metastasis; senescence; type I interferon
Mesh:
Substances:
Year: 2016 PMID: 27052162 PMCID: PMC4826807 DOI: 10.1016/j.celrep.2016.03.006
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423